Department of Otorhinolaryngology, Head and Neck Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Eur Arch Otorhinolaryngol. 2021 Feb;278(2):577-616. doi: 10.1007/s00405-020-06507-5. Epub 2020 Dec 19.
To develop a European White Paper document on oropharyngeal dysphagia (OD) in head and neck cancer (HNC). There are wide variations in the management of OD associated with HNC across Europe.
Experts in the management of specific aspects of OD in HNC across Europe were delegated by their professional medical and multidisciplinary societies to contribute to this document. Evidence is based on systematic reviews, consensus-based position statements, and expert opinion.
Twenty-four sections on HNC-specific OD topics.
This European White Paper summarizes current best practice on management of OD in HNC, providing recommendations to support patients and health professionals. The body of literature and its level of evidence on diagnostics and treatment for OD in HNC remain poor. This is in the context of an expected increase in the prevalence of OD due to HNC in the near future. Contributing factors to increased prevalence include aging of our European population (including HNC patients) and an increase in human papillomavirus (HPV) related cancer, despite the introduction of HPV vaccination in various countries. We recommend timely implementation of OD screening in HNC patients while emphasizing the need for robust scientific research on the treatment of OD in HNC. Meanwhile, its management remains a challenge for European professional associations and policymakers.
制定一份关于头颈部癌症(HNC)相关口咽吞咽困难(OD)的欧洲白皮书文件。欧洲各地在 HNC 相关 OD 的管理方面存在广泛差异。
由欧洲各专业医学和多学科协会指定的 HNC 特定 OD 管理方面的专家为该文件做出贡献。证据基于系统评价、基于共识的立场声明和专家意见。
24 个关于 HNC 特定 OD 主题的部分。
本欧洲白皮书总结了目前 HNC 相关 OD 管理的最佳实践,为支持患者和卫生专业人员提供了建议。HNC 相关 OD 的诊断和治疗的文献数量及其证据水平仍然较差。这是由于未来 HNC 导致 OD 的患病率预计会增加。患病率增加的因素包括欧洲人口(包括 HNC 患者)老龄化以及 HPV 相关癌症的增加,尽管在多个国家已经引入了 HPV 疫苗接种。我们建议在 HNC 患者中及时实施 OD 筛查,同时强调需要对 HNC 相关 OD 的治疗进行强有力的科学研究。与此同时,其管理仍然是欧洲专业协会和政策制定者面临的挑战。